ZetaGen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ZetaGen Therapeutics's estimated annual revenue is currently $2M per year.
- ZetaGen Therapeutics's estimated revenue per employee is $201,500
Employee Data
- ZetaGen Therapeutics has 10 Employees.
- ZetaGen Therapeutics grew their employee count by 0% last year.
ZetaGen Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Director Scientific Operations | Reveal Email/Phone |
4 | Laboratory Assistant | Reveal Email/Phone |
5 | Laboratory Technician | Reveal Email/Phone |
ZetaGen Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is ZetaGen Therapeutics?
ZetaGen Therapeutics, is an early stage life science company developing therapeutic solutions for large unmet needs in the regenerative medicine and oncology markets. We are commercializing a small molecule-based osteoinductive platform technology to develop bone growth products that activate a novel molecular pathway. Discovered serendipitously, ZetaGen's products have the potential to transform the treatment of bone-related injuries, procedures and diseases to deliver better outcomes for patients, doctors and payors.
keywords:N/AN/A
Total Funding
10
Number of Employees
$2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 10 | 0% | N/A |
#2 | $1.2M | 11 | -15% | N/A |
#3 | $1.4M | 11 | 22% | N/A |
#4 | $1.3M | 11 | -21% | N/A |
#5 | N/A | 11 | N/A | N/A |